Product Information
| Purity: |
Affinity purification |
| Storage: |
Store at -20 or -80°C. Avoid freeze/thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3 |
Catalog No: A70014
Histone H3K27me2 Polyclonal Antibody
Application:
WB (1:500-1:2000), IHC (1:50-1:200), IF (1:50-1:200), IP (1:50-1:200)
Cross-Reactivity: H, M, R, other (wide range)
Calculated MW: 15kDa
Species: Rabbit
Isotype: IgG
Purity: Affinity purification
Concentration: 1mg/mL
Storage:
Store at -20 or -80°C. Avoid freeze/thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3
Immunogen Information
Immunogen:
A synthetic methylated peptide corresponding to residues surrounding Lys27 of human histone H3
Gene ID: 8290
Swiss Prot: Q16695
Synonyms:
HIST1H3J; H3/j; H3FJ; Histone H3.1; Histone H3/a; Histone H3/b; Histone H3/c; Histone H3/d; Histone H3/f; Histone H3/h; Histone H3/I; Histone H3/j; Histone H3/k; Histone H3/I; HIST3H3
Background:
Histone H3 Lysine 27 (H3K27) methylation is correlated with transcription repression. Recently study has found that GSK126, a histone methyltransferase EZH2 inhibitor, decreases global H3K27me3 levels and effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines (1). Small molecule EPZ6438, another EZH2 inhibitor, specifically inhibits cellular H3K27 methylation leading to selective apoptotic killing of SMARCB1 mutant MRT Cells (2, 3). Meanwhile, study also finds that the expression level of Histone H3K27 trimethylation (H3K27me3) is low in human bladder cancer tissues (4). There is now evidence for both increased and decreased activity of enzymes controlling H3K27 methylation in cancer, suggesting that a precise balance of this methylation is critical for normal cell growth. Restoring a normal epigenetic condition could be a rational approach for cancer treatment and specialized prevention (5). H3K27 methylation statuses can be detected by our H3K27 methylation antibody series.
PDF:
SDS:
Reference:
1. McCabe MT, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. (2012) Nature 492(7427):108-12.
2. Knutson SK, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. (2013) Proc Natl Acad Sci U S A 110(19):7922-7.
3. Robert A Copeland. Protein methyltransferases in cancer. (2013) AACR Annual Meeting.
4. Cha TL, et al. Emodin Modulates epigenetic modifications and suppresses bladder carcinoma cell growth. (2013) Mol Carcinog.
5. Jonathan DL, et al. Deregulation of H3K27 methylation in cancer. (2010) Nature Genetics 42:100-101
